BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 25636144)

  • 1. Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
    Harel Z; Sood MM; Perl J
    Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):183-92. PubMed ID: 25636144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.
    Harel Z; Sholzberg M; Shah PS; Pavenski K; Harel S; Wald R; Bell CM; Perl J
    J Am Soc Nephrol; 2014 Mar; 25(3):431-42. PubMed ID: 24385595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban.
    Pelliccia F; Rosanio S; Marazzi G; Poggi S; Tanzilli A; Greco C; Gaudio C; Rosano G
    Int J Cardiol; 2016 Dec; 225():77-81. PubMed ID: 27716554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
    Voukalis C; Lip GY; Shantsila E
    Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oral anticoagulants in chronic kidney disease: ready for prime time?
    Ashley J; Sood MM
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):201-208. PubMed ID: 29570468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):997-1001. PubMed ID: 25392439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants in non-valvular atrial fibrillation.
    Potpara TS; Lip GY
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New anticoagulants: better knowledge, better prescriptions].
    Boehlen F; de Moerloose P
    Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
    Sardar P; Chatterjee S; Herzog E; Nairooz R; Mukherjee D; Halperin JL
    Can J Cardiol; 2014 Aug; 30(8):888-97. PubMed ID: 25064581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New oral anticoagulants in elderly patients.
    Barco S; Cheung YW; Eikelboom JW; Coppens M
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants: a review of new agents.
    Wanat MA
    Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.